Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 7/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.47 |
| ▸ | FAAH | O00519 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19272736 | 1.00 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL321096 | 0.96 | MGLL (0.64) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL15206463 | 0.90 | MGLL (0.56) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL27420754 | 0.86 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL5208692 | 0.86 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL17732171 | 0.86 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL10079339 | 0.86 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL15215618 | 0.86 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL22311909 | 0.86 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL13733359 | 0.86 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179467-B2 | Exenatide modifier and use thereof | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2021-11-23 | — | — | US | disclosed |
| US-20200347149-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEAGEN INC. | 2020-11-05 | — | — | US | disclosed |
| US-10808039-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10639381-B2 | Trioxacarcins, trioxacarcin#antibody conjugates, and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2020-05-05 | — | — | US | disclosed |
| EP-3321279-B1 | EXENATIDE MODIFIER AND USE THEREOF | BRIGHTGENE BIO MEDICAL TECH CO LTD (CN) | 2020-02-12 | — | — | EP | disclosed |
| US-10414826-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| EP-2320954-B1 | DIAGNOSTIC AGENTS SELECTIVE AGAINST METALLOPROTEASES | BRACCO IMAGING SPA (IT) | 2019-09-04 | — | — | EP | disclosed |
| EP-2922575-B1 | TRIOXACARCINS, TRIOXACARCIN-ANTIBODY CONJUGATES, AND USES THEREOF | HARVARD COLLEGE (US) | 2019-06-26 | — | — | EP | disclosed |
| EP-3434275-A1 | ASSAY FOR CANCER CELLS BASED ON THE USE OF AURISTATIN CONJUGATES WITH ANTIBODIES | Seattle Genetics, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180221504-A1 | TRIOXACARCINS, TRIOXACARCIN-ANTIBODY CONJUGATES, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-08-09 | — | — | US | disclosed |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | BRACCO IMAGING S.P.A. (IT) | 2008-12-25 | — | — | US | disclosed |
| US-20080300192-A1 | Auristatins Having an Aminobenzoic Acid Unit at the N Terminus | SEATTLE GENETICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300192-A1 | Auristatins Having an Aminobenzoic Acid Unit at the N Terminus | SEATTLE GENETICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080248053-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080248051-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080226657-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-20070134243-A1 | Antibody drug conjugates and methods | GENENTECH, INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2007008848-A2 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006095234-A2 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080248053-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | MMAB, CAD, VIM | MGLL 4677/4885PTGS1 4626/4885PTGS2 4832/4885 |
| US-10414826-B2 | Monomethylvaline compounds capable of conjugation to ligands | MMAB, CAD, VIM | MGLL 4454/4885PTGS1 4742/4885PTGS2 4834/4885 |
| US-10639381-B2 | Trioxacarcins, trioxacarcin#antibody conjugates, and uses thereof | C9, CES1, LYPLA1 | MGLL 1761/4885PTGS1 3221/4885PTGS2 3887/4885 |
| US-10808039-B2 | Monomethylvaline compounds capable of conjugation to ligands | MMAB, CAD, VIM | MGLL 4454/4885PTGS1 4742/4885PTGS2 4834/4885 |
| US-20080226657-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | MMAB, CAD, VIM | MGLL 4677/4885PTGS1 4626/4885PTGS2 4832/4885 |
| US-20080248051-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | MMAB, CAD, VIM | MGLL 4677/4885PTGS1 4626/4885PTGS2 4832/4885 |
| US-20070134243-A1 | Antibody drug conjugates and methods | BOD1L1, MKI67, CCNI | MGLL 4187/4885PTGS1 1967/4885PTGS2 1927/4885 |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | ITGA2B, ITGB2, ITGB1 | MGLL 4850/4885PTGS1 4338/4885PTGS2 4298/4885 |
| US-20180221504-A1 | TRIOXACARCINS, TRIOXACARCIN-ANTIBODY CONJUGATES, AND USES THEREOF | C9, CES1, LYPLA1 | MGLL 1861/4885PTGS1 3258/4885PTGS2 3912/4885 |
| US-11179467-B2 | Exenatide modifier and use thereof | GLP1R, GCGR, GIPR | MGLL 68/4885PTGS1 1262/4885PTGS2 2129/4885 |
| US-20200347149-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | MGLL 4454/4885PTGS1 4742/4885PTGS2 4834/4885 |
| US-20080300192-A1 | Auristatins Having an Aminobenzoic Acid Unit at the N Terminus | AURKB, AURKA, AURKC | MGLL 4854/4885PTGS1 4453/4885PTGS2 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.